Abarelix

DB00106ApprovedWithdrawnSmall molecule

Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the...

Mechanism: Abarelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion.
Curator reviewed
Primary indication: For palliative treatment of advanced prostate cancer.Curator reviewed
Formula / weight: C₇₂H₉₅ClN₁₄O₁₄ · 1416.09 g/mol (avg)

Resolves to

Compound

UNIIW486SJ5824CAS183552-38-7ChEMBLCHEMBL1252ChEBI337298PubChem16131215KEGGD02738

Clinical / RWD

RxNorm301739ATCL02BX01PharmGKBPA164754915

Structure

InChIKeyAIWRTTMUVOZGPW-HSPKUQOVSA-NSMILES

CC(C)C[C@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O

Targets

P30968GNRHR

What you can answer from here — as of September 12, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 7 drug categories

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Abarelix, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account